Posted by Michael Wonder on 09 Apr 2022
Upadacitinib, abrocitinib and tralokinumab for atopic dermatitis
8 April 2022 - A rare multiple technology assessment from NICE.
Abrocitinib and upadacitinib are not recommended, within their marketing authorisations, for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over.
Tralokinumab is not recommended, within its marketing authorisation, for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults.
